53m
Is Ionis’ Raised Revenue Outlook and Positive Phase 3 Data Shifting the Investment Case for IONS?
Ionis Pharmaceuticals reported third quarter revenue of US$157 million and reduced its net loss to US$129 million, while also raising its full-year 2025 revenue guidance to a range of US$875 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback